Genscript Biotech Corporation Genscript Biotech Corporation

Genscript Biotech Corporation

1548

Xếp hạng trong cổ phiếu #2023
Operating as an investment holding company, Genscript Biotech Corporation,... Operating as an investment holding company, Genscript Biotech Corporation, established in 2002 and headquartered in Nanjing, People's Republic of China, specializes in the global provision of innovative life science research solutions, encompassing both products and services. Its market presence spans North America, Europe, China, Japan, other Asia Pacific regions, and numerous international markets. The enterprise structures its operations into four key divisions: The Life Science Services and Products segment delivers a wide array of research offerings, such as gene and oligonucleotide synthesis, molecular cloning, protein and peptide engineering, antibody production, molecular diagnostic instruments, and genomic editing materials. These resources are instrumental for fundamental biological investigations, pharmaceutical and drug discovery, disease diagnostics, vaccine development, and applications in agriculture, environmental science, and food production. The Biologics Development Services division supports pharmaceutical, biotechnology, governmental, and academic institutions. It provides comprehensive services for the full lifecycle of therapeutic antibodies, from initial discovery through pre-clinical and clinical development, alongside pre-clinical and clinical development for plasmids and viruses, and broader gene and cell therapy development. Dedicated to industrial applications, the Industrial Synthetic Biology Products segment engineers non-pathogenic microbial strains and manufactures specialized enzymes. These enzymes find utility across the food processing, animal feed, pharmaceutical, and chemical sectors. Finally, the Cell Therapy unit focuses on the pioneering discovery and advanced development of chimeric antigen receptor T-cell (CAR-T) therapies, specifically designed to combat both liquid and solid malignant tumors.
Giá cổ phiếu
$4.45
Vốn hóa thị trường
$10.00B
Thay đổi (1 ngày)
1.63%
Thay đổi (1 năm)
114.95%
Quốc gia
HK
Giao dịch Genscript Biotech Corporation (1548)

Danh mục

Healthcare
Doanh thu của Genscript Biotech Corporation (1548)
Doanh thu vào Jun 2026 TTM: $844.00M
Theo các báo cáo tài chính gần đây của Genscript Biotech Corporation, doanh thu hiện tại của công ty (TTM) là $844.00M. Trong năm 2023, công ty đạt doanh thu $839.53M tăng so với doanh thu năm 2022, là $625.70M. Doanh thu là tổng số tiền công ty tạo ra từ việc bán hàng hóa hoặc dịch vụ. Không giống như lợi nhuận, doanh thu không trừ chi phí.
Lịch sử doanh thu của Genscript Biotech Corporation từ 2013 đến 2026
Doanh thu vào cuối mỗi năm
Năm Doanh thu Thay đổi
2026 (TTM) $844.00M 41.97%
2024 $594.49M -29.19%
2023 $839.53M 34.17%
2022 $625.70M 27.67%
2021 $490.10M 25.39%
2020 $390.85M 42.98%
2019 $273.35M 18.33%
2018 $231.02M 51.34%
2017 $152.65M 33.04%
2016 $114.74M 32.32%
2015 $86.71M 23.88%
2014 $69.99M 16.45%
2013 $60.10M 0.00%
Doanh thu của các công ty hoặc đối thủ tương tự
Công ty Doanh thu Chênh lệch doanh thu Quốc gia
$12.62B 1,395.77%
US
$2.23B 163.98%
US
$15.74B 1,765.44%
AU
$6.02B 613.42%
NL
- -
CH